Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26874901

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Mar
First author
Chan A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Mar;17(3):268-270. doi: 10.1016/S1470-2045(15)00623-3.
    note
    Source null
    related pmid
    26874902
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2016 May;17(5):e176-7. doi: 10.1016/S1470-2045(16)30018-3.
    note
    Source null
    related pmid
    27301039
    relationship
    Comment in

Authors and identifiers

  1. name
    Chan A
    type
    Author
  2. name
    Delaloge S
    type
    Author
  3. name
    Holmes FA
    type
    Author
  4. name
    Moy B
    type
    Author
  5. name
    Iwata H
    type
    Author
  6. name
    Harvey VJ
    type
    Author
  7. name
    Robert NJ
    type
    Author
  8. name
    Silovski T
    type
    Author
  9. name
    Gokmen E
    type
    Author
  10. name
    von Minckwitz G
    type
    Author
  11. name
    Ejlertsen B
    type
    Author
  12. name
    Chia SKL
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Chan A
    type
    Author
  2. name
    Delaloge S
    type
    Author
  3. name
    Holmes FA
    type
    Author
  4. name
    Moy B
    type
    Author
  5. name
    Iwata H
    type
    Author
  6. name
    Harvey VJ
    type
    Author
  7. name
    Robert NJ
    type
    Author
  8. name
    Silovski T
    type
    Author
  9. name
    Gokmen E
    type
    Author
  10. name
    von Minckwitz G
    type
    Author
  11. name
    Ejlertsen B
    type
    Author
  12. name
    Chia SKL
    type
    Author
bibliography ids
  1. nci-bib-82ac936d921fc822eaa12952
book metadata
content sha256
953b8a77f85ccac45b8131151ce2f3f093425d2a56af94c1d860e0392759e094
document type
citation
dois
  1. 10.1016/S1470-2045(15)00551-3
electronic publication date
display
2016 Feb 10
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:26874901
immutable id
pubmed:26874901@953b8a77f85ccac45b8131151ce2f3f093425d2a56af94c1d860e0392759e094
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
3
name
The Lancet. Oncology
nlm unique id
100957246
pages
367-377
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Mar;17(3):268-270. doi: 10.1016/S1470-2045(15)00623-3.
    note
    Source null
    related pmid
    26874902
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2016 May;17(5):e176-7. doi: 10.1016/S1470-2045(16)30018-3.
    note
    Source null
    related pmid
    27301039
    relationship
    Comment in
outcomes validated
false
pmid
26874901
provenance
batch id
948d34b0dea86780a31d
provider
NCBI PubMed ESummary
record sha256
3c59d527557bb0a7080c23e62628ecf3e056cdb47cda750cdb3ae365cc77d632
response sha256
11c34185eb9e4ea0d3c4d255d31806495349b0f097d492c4e135946541bf4bb5
retrieved at
2026-09-09T23:47:15.495091+00:00
publication date
display
2016 Mar
precision
month
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26874901/
title
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice